Back to Menu
Basis for Lung Cancer Diagnosis
1. Clinical presentation assessment
Through medical history taking and physical examination, clinicians evaluate symptoms such as cough, hemoptysis, and chest pain, as well as associated risk factors.
2. Imaging examinations
Low-dose spiral CT is used for early screening; contrast-enhanced CT and PET-CT are used to assess tumor extent and metastasis.
3. Pathological biopsy
The diagnostic gold standard. Tissue is obtained via bronchoscopy or percutaneous biopsy to determine histologic type and molecular characteristics.
4. Bronchoscopy
Allows direct visualization of airway lesions and sampling. Endobronchial ultrasound can improve the accuracy of mediastinal lymph node sampling.
5. Tumor marker testing
Markers such as CEA and NSE are measured to aid diagnosis and monitor treatment response, with greater value in dynamic follow-up.
6. Molecular testing
Testing for EGFR, ALK, PD-L1, and other biomarkers provides a basis for targeted therapy and immunotherapy, enabling precision medicine.
7. Pleural effusion evaluation
Biochemical and cytological analyses of pleural fluid are performed to detect malignant cells, supporting diagnosis and staging.
8. Pulmonary function testing
Assesses baseline pulmonary function and provides important information regarding surgical feasibility.
Conclusion
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that lung cancer is a disease that severely endangers health, and late-stage diagnosis adversely affects treatment outcomes. The key lies in early diagnosis and individualized treatment: regular screening should be used to enable early detection, and comprehensive strategies integrating surgery, radiotherapy, and minimally invasive approaches should be developed according to stage and subtype to substantially improve cure rates and quality of survival.
Basis for Lung Cancer Diagnosis
1. Clinical presentation assessment
Through medical history taking and physical examination, clinicians evaluate symptoms such as cough, hemoptysis, and chest pain, as well as associated risk factors.
2. Imaging examinations
Low-dose spiral CT is used for early screening; contrast-enhanced CT and PET-CT are used to assess tumor extent and metastasis.
3. Pathological biopsy
The diagnostic gold standard. Tissue is obtained via bronchoscopy or percutaneous biopsy to determine histologic type and molecular characteristics.
4. Bronchoscopy
Allows direct visualization of airway lesions and sampling. Endobronchial ultrasound can improve the accuracy of mediastinal lymph node sampling.
5. Tumor marker testing
Markers such as CEA and NSE are measured to aid diagnosis and monitor treatment response, with greater value in dynamic follow-up.
6. Molecular testing
Testing for EGFR, ALK, PD-L1, and other biomarkers provides a basis for targeted therapy and immunotherapy, enabling precision medicine.
7. Pleural effusion evaluation
Biochemical and cytological analyses of pleural fluid are performed to detect malignant cells, supporting diagnosis and staging.
8. Pulmonary function testing
Assesses baseline pulmonary function and provides important information regarding surgical feasibility.
Conclusion
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that lung cancer is a disease that severely endangers health, and late-stage diagnosis adversely affects treatment outcomes. The key lies in early diagnosis and individualized treatment: regular screening should be used to enable early detection, and comprehensive strategies integrating surgery, radiotherapy, and minimally invasive approaches should be developed according to stage and subtype to substantially improve cure rates and quality of survival.